Table 1.
Demographic and clinical characteristics of the study population.
| Characteristic | Total Population (n = 356) |
|---|---|
| Sex, n (%) | |
| Male/female | 201 (56.5)/155 (43.5) |
| Age (years) | |
| Mean (± SD) | 64.3 ± 11.92 |
| Median [Q1; Q3] | 65.0 [59; 73] |
| Range (min–max) | (26–87) |
| Body mass index (kg/m2) | |
| Mean (± SD) | 28.7 ± 4.05 |
| Median [Q1; Q3] | 28.0 [26; 30] |
| Range (min–max) | (18–49) |
| No. of patients with hypertension, n (%) | 339 (95.2) |
| Duration of hypertension (years), (n = 339) * | |
| Mean (± SD) | 9.15 ± 6.56 |
| Median [Q1; Q3] | 7.80 [4.8; 13] |
| Range (min–max) | (0.1–43.8) |
| No. of patients with ischemic heart disease, n (%) | 243 (65.7) |
| Duration of ischemic heart disease (years) ** | |
| Mean (± SD) | 6.65 ± 5.88 |
| Median [Q1; Q3] | 5.00 [2.5; 8.7] |
| Range (min–max) | (0.1–35.8) |
| Duration of BIS and ASA free combination (months) | |
| Mean (± SD) | 17.8 ± 26.57 |
| Median [Q1; Q3] | 9.0 [5; 16.5] |
| Range (min–max) | (1–187) |
| BIS free dose (mg) | |
| Mean (± SD) | 5.6 ± 1.63 |
| Median [Q1; Q3] | 5.0 [5; 5] |
| Range (min–max) | (5–10) |
| ASA free dose (mg) | |
| Mean (± SD) | 75.0 ± 0.00 |
| Median [Q1; Q3] | 75.0 [75; 75] |
| Range (min–max) | (75–75) |
| Switch to FDC before study (weeks) | |
| Mean (± SD) | 6.3 ± 3.7 |
| Median [Q1; Q3] | 5.0 [4; 8] |
| Range (min–max) | (4–56) |
| BIS + ASA FDC dose (mg) | |
| 5/75 | 313 (87.9) |
| 5/100 | 0 (0.0) |
| 10/75 | 43 (12.1) |
| 10/100 | 0 (0.0) |
BIS: bisoprolol; ASA: aspirin; FDC: fixed-dose combination; SD: standard deviation; Q: quartile. * 17 (4.8%) missing data; ** 122 (34.3%) missing data.